Improved Noninvasive prediction of Liver Fibrosis by Liver Stiffness Measurement in Patients with Nonalcoholic Fatty Liver Disease Accounting for Controlled Attenuation Parameter Values
Salvatore Petta,Vincent Wai-Sun Wong,Calogero Cammà,Jean-Baptiste Hiriart,Grace Lai-Hung Wong,Fabio Marra,Julien Vergniol,Anthony W.H. Chan,Vito Di Marco,Wassil Merrouche,Henry Lik-Yuen Chan,Marco Barbara,Brigitte Le-Bail,Umberto Arena,Antonio Craxì,Victor de Ledinghen +15 more
Reads0
Chats0
TLDR
In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography.About:
This article is published in Hepatology.The article was published on 2017-04-01 and is currently open access. It has received 168 citations till now. The article focuses on the topics: Nonalcoholic fatty liver disease.read more
Citations
More filters
Journal ArticleDOI
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
TL;DR: The current state of the noninvasive assessment of liver disease in NAFLD is summarized, and an expert synthesis of how these nonin invasive tools could be utilized in clinical practice is provided.
Journal ArticleDOI
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Peter J Eddowes,Magali Sasso,Michael Allison,Emmanouil Tsochatzis,Quentin M. Anstee,David Sheridan,Indra Neil Guha,Jeremy F. L. Cobbold,Jonathan J Deeks,Valérie Paradis,Pierre Bedossa,Philip N. Newsome,Philip N. Newsome +12 more
TL;DR: In a prospective analysis of patients with NAFLD, FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) found to be effective in assessing liver steatosis and fibrosis, respectively, with AUROC values ranging from 0.70 to 0.89.
Journal ArticleDOI
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti,Emmanouil Tsochatzis,Jérôme Boursier,Laurent Castera,Nora Cazzagon,Mireen Friedrich-Rust,Salvatore Petta,Maja Thiele +7 more
TL;DR: In this article, the authors provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis.
Journal ArticleDOI
Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations.
Giovanna Ferraioli,Vincent Wai-Sun Wong,Laurent Castera,Annalisa Berzigotti,Ioan Sporea,Christoph F. Dietrich,Byung Ihn Choi,Stephanie R. Wilson,Masatoshi Kudo,Richard G. Barr +9 more
TL;DR: This set of guidelines updates the first version, published in 2015, and is aimed at assessing the usefulness of elastography in the management of liver diseases.
Journal ArticleDOI
Nonalcoholic fatty liver disease: Evolving paradigms
Amedeo Lonardo,Fabio Nascimbeni,Mauro Maurantonio,Alessandra Marrazzo,Luca Rinaldi,Luigi Elio Adinolfi +5 more
TL;DR: NAFLD is highly prevalent in certain cohorts of individuals who are thus potentially amenable to selective screening strategies, intensive follow-up schedules for early identification of liver-related and extrahepatic complications and in whom earlier and more aggressive treatment schedules should be carried out whenever possible.
References
More filters
Journal ArticleDOI
Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
Vlad Ratziu,Frédéric Charlotte,A. Heurtier,Sophie Gombert,Philippe Giral,Eric Bruckert,André Grimaldi,Frédérique Capron,Thierry Poynard +8 more
TL;DR: Histologic lesions of NASH are unevenly distributed throughout the liver parenchyma; therefore, sampling error of liver biopsy can result in substantial misdiagnosis and staging inaccuracies.
Journal ArticleDOI
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt,Hannes Hagström,Patrik Nasr,Mats Fredrikson,Per Stål,Stergios Kechagias,Rolf Hultcrantz +6 more
TL;DR: NAFLD patients have increased risk of death, with a high risk ofdeath from cardiovascular disease and liver‐related disease, and the NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease‐specific mortality.
Journal ArticleDOI
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong,Maria Aguilar,Ramsey Cheung,Ramsey Cheung,Ryan B. Perumpail,Stephen A. Harrison,Zobair M. Younossi,Zobair M. Younossi,Aijaz Ahmed +8 more
TL;DR: Patients with NASH are less likely to undergo liver transplantation (LT) andLess likely to survive for 90 days on the waitlist than patients with HCV, ALD, or HCV and ALD.
Journal ArticleDOI
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
Vincent Wai-Sun Wong,Julien Vergniol,Grace Lai-Hung Wong,Juliette Foucher,Henry Lik-Yuen Chan,Brigitte Le Bail,Paul Cheung-Lung Choi,Mathurin Kowo,Anthony W.H. Chan,Wassil Merrouche,Joseph J.Y. Sung,Victor de Ledinghen +11 more
TL;DR: Transient elastography is accurate in most NAFLD patients and is useful as a screening test to exclude advanced fibrosis, and liver biopsy may be considered in patients with liver stiffness of at least 7.9 kPa.
Journal ArticleDOI
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease
TL;DR: Liver biopsy size strongly influences the grading and staging of chronic viral hepatitis and the use of fine needles should be discouraged in this setting.